|
AP1G1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.32079999954394E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65655999999625E-05 |
| Normal-vs-Stage2 |
1.378280E-02 |
| Normal-vs-Stage3 |
5.68759999985957E-07 |
| Normal-vs-Stage4 |
3.35340000212625E-08 |
| Stage1-vs-Stage2 |
3.561200E-01 |
| Stage1-vs-Stage3 |
6.424300E-02 |
| Stage1-vs-Stage4 |
1.867780E-02 |
| Stage2-vs-Stage3 |
5.538400E-02 |
| Stage2-vs-Stage4 |
1.348230E-02 |
| Stage3-vs-Stage4 |
4.412800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.21020000038486E-07 |
| Normal-vs-AfricanAmerican |
2.454100E-02 |
| Normal-vs-Asian |
8.37820000000322E-05 |
| Caucasian-vs-AfricanAmerican |
3.665200E-01 |
| Caucasian-vs-Asian |
9.710800E-01 |
| AfricanAmerican-vs-Asian |
4.023200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.07899999999017E-06 |
| Normal-vs-Female |
1.65669999996343E-06 |
| Male-vs-Female |
7.307000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.5743000000017E-05 |
| Normal-vs-Age(41-60Yrs) |
1.53388999999393E-05 |
| Normal-vs-Age(61-80Yrs) |
8.37860000046931E-07 |
| Normal-vs-Age(81-100Yrs) |
1.096020E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.112800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.369810E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.094600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.682400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.710000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.277600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.846270E-02 |
| Classical-VS-Follicular |
1.151570E-01 |
| Classical-VS-Other |
1.069400E-01 |
| Classical-VS-Normal |
8.32630000000556E-05 |
| Tall-VS-Follicular |
1.901210E-01 |
| Tall-VS-Other |
6.403600E-01 |
| Tall-VS-Normal |
1.03520000005464E-06 |
| Follicular-VS-Other |
3.310400E-01 |
| Follicular-VS-Normal |
2.43389999999843E-05 |
| Other-VS-Normal |
1.424670E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.52149999999018E-05 |
| Normal-vs-N1 |
2.86340000044127E-07 |
| N0-vs-N1 |
9.966000E-02 |
|
|
